DE610436T1 - Detektion des Hepatis-C Virus. - Google Patents

Detektion des Hepatis-C Virus.

Info

Publication number
DE610436T1
DE610436T1 DE0610436T DE92924761T DE610436T1 DE 610436 T1 DE610436 T1 DE 610436T1 DE 0610436 T DE0610436 T DE 0610436T DE 92924761 T DE92924761 T DE 92924761T DE 610436 T1 DE610436 T1 DE 610436T1
Authority
DE
Germany
Prior art keywords
hcv
specific
peptide
antigenic
polynucleotide sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
DE0610436T
Other languages
English (en)
Inventor
Shui-Wan Chan
Peter Simmonds
Peng Yap
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Common Services Agency
Original Assignee
Common Services Agency
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26299894&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE610436(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB919124696A external-priority patent/GB9124696D0/en
Priority claimed from GB929213362A external-priority patent/GB9213362D0/en
Application filed by Common Services Agency filed Critical Common Services Agency
Publication of DE610436T1 publication Critical patent/DE610436T1/de
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1081—Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
    • C07K16/109—Hepatitis C virus; Hepatitis G virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/706—Specific hybridization probes for hepatitis
    • C12Q1/707—Specific hybridization probes for hepatitis non-A, non-B Hepatitis, excluding hepatitis D
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/18—Togaviridae; Flaviviridae
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/18—Togaviridae; Flaviviridae
    • G01N2333/183—Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus) or border disease virus
    • G01N2333/186—Hepatitis C; Hepatitis NANB
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/82—Hepatitis associated antigens and antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)

Claims (34)

PATENTANSPRÜCHE
1. Polynucleotid-Sequenz, eindeutig für Hepatitis-C-Virus, Typ 3 oder 4 (HCV-3 oder HCV-4).
2. Polynucleotid-Sequenz nach Anspruch 1, welche eine cDNA-Sequenz ist.
3. HCV-3- oder HCV-4-spezifische Polynucleotid-Sequenz aus dem Kern, NS3-. NS4- oder NS5-Regionen.
4. HCV-3- oder HCV-4-spezi fische Polynucleotid-Sequenz innerhalb der in Fig.1 und la, 9a, 13 und 15a dargestellten HCV-3- oder HCV-4- Sequenzen.
5. HCV-3- oder HCV-4-Polynucleotid-Sequenz, die ein antigenes Peptid codiert.
6. HCV-3- oder HCV-4-spezifische Polynucleotid-Sequenz, die C-100-, 5-1-1-, C33- oder C22-Peptide codiert, welche für HCV-3 oder HCV-4 eindeutige Sequenzänderungen aufweisen.
7. HCV-3-Polynucleotid-Sequenz, codierend das
Polypeptid KPALVPDKEVLYQQYDEM oder das
Polypeptid ECSQAAPYIEQAQVIAHQF oder
Polypeptide mit weitgehend äquivalenter Antigenitat.
8. Hepatiti s-C-Vi rus, Typ 2 (HCV-2)-Polynucleotid-Sequenz, codierend das Polypeptid R(A/V)V(V/I)(A/T)PDKE(1/V)LYEAFDEM oder das
Polypeptid ECAS(K/R)AALIEEGQR(M/I)AEML oder
Polypeptide mit weitgehend äquivalenter Antigenitat.
30
9. Antigenes, HCV-3- oder HCV-4-spezifisches Peptid.
10. Antigenes, HCV-3- oder HCV-4-spezifisches Peptid aus dem Kern, NS3- oder NS5-Regionen
11. Antigenes, HCV-3-spezifisches Peptid innerhalb der in Fig. 3, 5 oder 7 dargestellten Sequenzen.
12. Antigenes, HCV-3- oder HCV-4-spezifisches Peptid, welches den Proteinen C-IOO, 5-1-1, C33 oder C22 entspricht, die für HCV-3 oder HCV-4 eindeutige Sequenzänderungen aufweisen.
13. Antigenes NS4-Peptid, spezifisch auf HCV-3 oder HCV-4.
14. Antigenes, HCV-2-spezifisches Peptid, welches
R(A/V)V(V/I)(A/T)PDKE(1/V)LYEAFDEM oder
ECASiK/FOAALIEEGQRCM/DAEML ist.
15. Antigenes, HCV-3-spezifisches Peptid, welches
KPALVPDKEVLYQQYDEM oder
ECSQAAPYIEQAQVIAHQF ist.
16. Antigenes NS4-Peptid, spezifisch auf HCV-4, welches die HCV-4-Sequenz im wesentlichen von der Position 1691 bis 1708 oder die Sequenz im wesentlichen von der Position 1710 bis 1728 aufweist.
17. Fusionspeptid, welches mindestens zwei der Antigene von Anspruch 9 bis 16 aufweist.
18. Fusionspeptid nach Anspruch 17, welches mindestens eines der Antigene von Anspruch 9 bis 16 aufweist, fusioniert mit ß-Galactosidase, GST, trp E oder polyedrisch codierender Sequenz.
19. Peptid nach Anspruch 9 bis 18, welches markiert ist.
20. Impfstoffzubereitung mit einem Antigen nach Anspruch 9 bis 18.
21. Antikörper zu dem antigenen Peptid nach Anspruch 9 bis 19.
22. Immunoassay-Vorrichtung, die ein festes Substrat mit daran gebundenem Antigen nach Anspruch 9 bis 19 aufweist.
23. Vorrichtung nach Anspruch 22 für HCV-Screening, welche eine Mischung von Antigenen aufweist.
0670 436
24. Vorrichtung nach Anspruch 23, bei welcher die Antigene aus dem Kern und NS4-Regionen sind.
25. Vorrichtung nach Anspruch 22 zum HCV-Typisieren, die eine Platte mit einer Reihe von Eingrenzungen aufweist, welche HCV-I-, HCV-2- bztw. HCV-3-spezifische Antigenen enthalten.
26. Vorrichtung nach Anspruch 25, die ferner eine Stelle aufweist, die ein HCV-4-spezifisches Antigen enthält.
27. Immunoassay-Vorrichtung, die ein festes Substrat mit daran gebundenem Antikörper nach Anspruch 21 aufweist.
28. Verfahren zum in vitro-Testen auf HCV, umfassend reverse Transkription jedes vorliegenden HCV-Polynucleotids und Amplification durch Polymerase-Kettenreaktion (PCR) und Detektieren des amplifizierten HCV-Polynucleotids unter Einsatz einer HCV-2-, HCV-3- oder HCV-4-spezifischen Polynucleotid-Sonde.
29. Verfahren zum in vitro-Testen auf HCV nach Anspruch 28, bei welchem die für PCR eingesetzten Primer aus denen ausgewählt werden, die in Tabelle 1 angegeben sind.
30. Verfahren zum in vitro-HCV-Typisieren, welches umfaßt:
- Ausführen von Endonuclease-Spaltung einer HCV enthaltenden Probe unter Einsatz von ScrFI oder Haelll/Rsal-Endonuclease sowie
Vergleichen des Restriktionsmusters mit charakteristischen Typ-spezifischen Mustern.
31. Verfahren nach Anspruch 30 oder 31, welches ferner in einem separaten oder vereinten Spaltung Hinfl einsetzt.
32. Verfahren zum in vitro-HCV-Typisieren, welches umfaßt:
Ausführen von Endonuclease-Spaltung einer HCV enthaltenden Probe unter Einsatz von ScrFI-Endonuclease, wobei das Restriktionsmuster charakteristisch ist für HCV-I, HCV-2 und HCV-3;
Ausführen von Endonuclease-Spaltung unter Einsatz von Hinfl-Endonuclease, deren Restriktionsmuster charakteristisch für HCV-4 ist.
33. Verfahren zum in vitro-Screening einer Probe für HCV-Antikörper, welches Verfahren umfaßt:
Ausführen eines Immunoassays unter Einsatz einen antigenen Peptids nach Anspruch 1 bis 19 oder einer Mischung davon; sowie
Detektieren jedes erzeugten Antikörper-Antigen-Komplexes.
10
34. Verfahren zum in vitro-HCV-Antikörper-Typisieren, welches separates Inkontaktbringen einer potentiell Antikörper-enthaltenden Probe oder Proben mit einer Reihe von HCV-Typ-spezifischen Antigenen; und Detektieren jedes mit einem Typ-spezifischen Antigen erzeugten Antikörper-Antigen-Komplexes.
DE0610436T 1991-11-21 1992-11-20 Detektion des Hepatis-C Virus. Pending DE610436T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB919124696A GB9124696D0 (en) 1991-11-21 1991-11-21 Hepatitis c virus
GB929213362A GB9213362D0 (en) 1992-06-24 1992-06-24 Hcv-3 virus
PCT/GB1992/002143 WO1993010239A2 (en) 1991-11-21 1992-11-20 Hepatitis-c virus testing

Publications (1)

Publication Number Publication Date
DE610436T1 true DE610436T1 (de) 1995-08-03

Family

ID=26299894

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69232906T Expired - Lifetime DE69232906T2 (de) 1991-11-21 1992-11-20 Detektion des Hepatis-C Virus.
DE0610436T Pending DE610436T1 (de) 1991-11-21 1992-11-20 Detektion des Hepatis-C Virus.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE69232906T Expired - Lifetime DE69232906T2 (de) 1991-11-21 1992-11-20 Detektion des Hepatis-C Virus.

Country Status (10)

Country Link
US (6) US5763159A (de)
EP (1) EP0610436B9 (de)
JP (1) JP3688290B2 (de)
AT (1) ATE231557T1 (de)
AU (1) AU671967B2 (de)
CA (1) CA2123875C (de)
DE (2) DE69232906T2 (de)
ES (1) ES2065863T3 (de)
FI (1) FI113967B (de)
WO (1) WO1993010239A2 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6667387B1 (en) 1996-09-30 2003-12-23 N.V. Innogenetics S.A. HCV core peptides
US6709828B1 (en) 1992-03-06 2004-03-23 N.V. Innogenetics S.A. Process for the determination of peptides corresponding to immunologically important epitopes and their use in a process for determination of antibodies or biotinylated peptides corresponding to immunologically important epitopes, a process for preparing them and compositions containing them
EP1878797B1 (de) * 1992-07-16 2010-04-28 Advanced Life Science Institute, Inc Antigene Peptide zur Gruppierung des Hepatitis-C-Virus, Kit damit und Verfahren zur Gruppierung unter Verwendung dieses Kits
CA2139100C (en) * 1993-04-27 2009-06-23 Geert Maertens New sequences of hepatitis c virus genotypes and their use as therapeutic and diagnostic agents
US7255997B1 (en) 1993-04-27 2007-08-14 N.V. Innogenetics S.A. Sequences of hepatitis C virus genotypes and their use as therapeutic and diagnostic agents
AU695259B2 (en) * 1993-05-05 1998-08-13 Common Services Agency Hepatitis-C virus type 4, 5 and 6
WO1994027153A1 (en) 1993-05-10 1994-11-24 Chiron Corporation Methods of typing hepatitis c virus and reagents for use therein
EP0729973A4 (de) * 1993-10-29 1998-12-30 Srl Inc Eine antigene peptidverbindung und ein immunoassay-verfahren
JPH10503364A (ja) * 1994-05-10 1998-03-31 ザ ジェネラル ホスピタル コーポレーション Ｃ型肝炎ウイルスのアンチセンス阻害
EP1076092A3 (de) 1994-10-21 2001-03-28 Innogenetics N.V. Sequenzen von Hepatitis-C-Virus Typ 10, und dessen Verwendungen als vorbeugende. therapeutische und diagnostische Mitteln
JPH0967395A (ja) * 1995-08-31 1997-03-11 S R L:Kk 抗原ペプチド化合物および免疫学的測定方法
JPH10104237A (ja) * 1996-09-27 1998-04-24 S R L:Kk 免疫測定用担体及びそれを用いた免疫測定方法
WO2000063444A2 (en) * 1999-04-14 2000-10-26 Institut Pasteur Method for detecting hepatitis c virus with hybridomas
US6562346B1 (en) 1999-10-27 2003-05-13 Chiron Corporation Activation of HCV-specific T cells
AU7446501A (en) * 2000-06-14 2001-12-24 J.Mitra And Co. Ltd. Diagnostic kit for invitro detection of hepatitis c
US20030232055A1 (en) * 2000-07-31 2003-12-18 Ruslan Medzhitov Innate immune system-directed vaccines
US20030175287A1 (en) * 2001-01-03 2003-09-18 Yale University Innate immune system-directed vaccines
US7424409B2 (en) * 2001-02-20 2008-09-09 Context-Based 4 Casting (C-B4) Ltd. Stochastic modeling of time distributed sequences
US20030152942A1 (en) * 2001-05-09 2003-08-14 Lance Fors Nucleic acid detection in pooled samples
US7196183B2 (en) 2001-08-31 2007-03-27 Innogenetics N.V. Hepatitis C virus genotype, and its use as prophylactic, therapeutic and diagnostic agent
GB0210535D0 (en) * 2002-05-08 2002-06-19 Novartis Ag Organic compounds
US8124747B2 (en) 2003-08-29 2012-02-28 Innogenetics HCV clade and prototype sequences thereof
RU2456617C2 (ru) * 2010-05-19 2012-07-20 Федеральное бюджетное учреждение науки "Государственный научный центр вирусологии и биотехнологии "Вектор" (ФБУН ГНЦ ВБ "Вектор") Панель сывороток, содержащих антитела к антигенам hcv разных субтипов
RU2588656C2 (ru) * 2011-01-13 2016-07-10 Орто-Клиникал Дайэгностикс, Инк. Триплетный антиген treponema pallidum
WO2013150450A1 (en) * 2012-04-02 2013-10-10 Universidade Do Porto Hcv homolog fragments, cell-lines and applications thereof
EP2959915A1 (de) 2014-06-23 2015-12-30 Institut Pasteur Chimäres Dengue-Virus-Polyepitop aus Fragmenten nichtstruktureller Proteine und deren Verbindung in einer immunogenen Zusammensetzung gegen Dengue-Virus-Infektion

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU216017B (hu) * 1987-11-18 1999-04-28 Chiron Corp. Eljárás HCV-1 polipeptidek, HCV-1 polinukleotidok, rekombináns vektorok és gazdasejtek, valamint immunesszé kit, hepatitis C vírusfertőzés elleni vakcinák, a fertőzés kimutatására szolgáló diagnosztikumok előállítására, és immunvizsgálati és vírustenyészt
HU225068B1 (en) * 1989-03-17 2006-05-29 Chiron Corp Process for producing diagnostics and vaccine of nanbh
RO113059B1 (ro) * 1989-05-18 1998-03-30 Chiron Corp Polinucleotida capabila de hibridizare pe o secventa hcv, metoda pentru detectarea unei secvente hcv si procedeu de eliminare a hcv din sange
DK0414475T3 (da) * 1989-08-25 1998-02-09 Chiron Corp Fremgangsmåder til dyrkning af HCV i B- eller T-lymfocyt-cellelinier
US5372928A (en) * 1989-09-15 1994-12-13 Chiron Corporation Hepatitis C virus isolates
AU638304B2 (en) * 1989-12-22 1993-06-24 Abbott Laboratories Hepatitis c assay
EP0435229A1 (de) * 1989-12-27 1991-07-03 Sanwa Kagaku Kenkyusho Co., Ltd. DNS-Gen von einem Non-A Non-B Hepatitis-Virus, seine Klonierung und Verwendung
KR940000755B1 (ko) * 1990-02-16 1994-01-29 유나이티드 바이오메디칼 인코오포레이티드 Hcv에 대한 항체 검출, hcv 감염의 진단 및 백신으로서의 그 예방에 특히 적합한 합성 펩티드
US5747239A (en) * 1990-02-16 1998-05-05 United Biomedical, Inc. Synthetic peptides specific for the detection of antibodies to HCV, diagnosis of HCV infection and preventions thereof as vaccines
HU217025B (hu) * 1990-04-04 1999-11-29 Chiron Corp. Hepatitis C vírus-(HCV) antigénkészítmények az anti-HCV-antitestek kimutatására immunoassay-kben
EP0464287A1 (de) * 1990-06-25 1992-01-08 The Research Foundation for Microbial Diseases of Osaka University Non-A, Non-B Hepatitis Virus genomisches DNS und Antigenpolypeptide
EP0468657A3 (en) * 1990-07-09 1992-02-05 Tonen Corporation Non-a non b hepatitis-specific antigen and its use in hepatitus diagnosis
CA2047792C (en) * 1990-07-26 2002-07-02 Chang Y. Wang Synthetic peptides specific for the detection of antibodies to hcv, diagnosis of hcv infection and prevention thereof as vaccines
CA2089080C (en) * 1990-08-10 2007-04-03 Michael Houghton Nanbv diagnostics: polynucleotides useful for screening for hepatitis c virus
DK0770679T4 (da) * 1990-11-03 2010-05-10 Siemens Healthcare Diagnostics HCV-specifikke peptider, sammensætninger dertil og anvendelse deraf
DE69233234T2 (de) * 1991-05-08 2004-08-05 Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville Genomische hcv-sequenzen für diagnostik und therapie
US5428145A (en) * 1991-08-09 1995-06-27 Immuno Japan, Inc. Non-A, non-B, hepatitis virus genome, polynucleotides, polypeptides, antigen, antibody and detection systems
EP0532167A3 (en) * 1991-08-09 1993-03-31 Immuno Japan Inc. Non-a, non-b hepatitis virus genome, polynucleotides, polypeptides, antigen, antibody and detection systems
CA2139100C (en) * 1993-04-27 2009-06-23 Geert Maertens New sequences of hepatitis c virus genotypes and their use as therapeutic and diagnostic agents
WO1994027153A1 (en) * 1993-05-10 1994-11-24 Chiron Corporation Methods of typing hepatitis c virus and reagents for use therein
EP3128216B1 (de) * 2015-08-07 2019-03-13 Claverham Limited Hydraulikventil

Also Published As

Publication number Publication date
CA2123875C (en) 2005-05-24
AU3088792A (en) 1993-06-15
US20110287410A1 (en) 2011-11-24
AU671967B2 (en) 1996-09-19
US20070128221A1 (en) 2007-06-07
DE69232906D1 (de) 2003-02-27
US5763159A (en) 1998-06-09
CA2123875A1 (en) 1993-05-27
US8318421B2 (en) 2012-11-27
US20130164733A1 (en) 2013-06-27
JP3688290B2 (ja) 2005-08-24
FI942369A (fi) 1994-07-19
DE69232906T2 (de) 2004-01-15
FI942369A0 (fi) 1994-05-20
ES2065863T3 (es) 2003-09-01
WO1993010239A3 (en) 1993-07-22
EP0610436A1 (de) 1994-08-17
FI113967B (fi) 2004-07-15
US20100266624A1 (en) 2010-10-21
JPH07501442A (ja) 1995-02-16
EP0610436B9 (de) 2003-03-26
WO1993010239A2 (en) 1993-05-27
ES2065863T1 (es) 1995-03-01
EP0610436B1 (de) 2003-01-22
US7976849B2 (en) 2011-07-12
US20030198946A1 (en) 2003-10-23
US7179470B2 (en) 2007-02-20
US7709006B2 (en) 2010-05-04
ATE231557T1 (de) 2003-02-15

Similar Documents

Publication Publication Date Title
DE610436T1 (de) Detektion des Hepatis-C Virus.
DE69030124T2 (de) Synthetische Antigene zum Nachweis von Antikörpern gegen Hepatitis C-Virus
KUNKEL Macroglobulins and high molecular weight antibodies
Boyce et al. Peptidosteroidal receptors for opioid peptides. Sequence-selective binding using a synthetic receptor library
US5670312A (en) Method of obtaining diagnostic reagents, assays and therapeutics based on clinical manifestations of a disease
ATE551423T1 (de) Sequenzen von hepatitis c virus-genotypen sowie ihre verwendungen als therapeutika und diagnostika
DE175360T1 (de) Antikoerper gegen petide und ihre verwendung zum nachweis von onkogene-produkten.
DE69434117T2 (de) Verfahren zur typisierung von hepatitis c viren und dafür zu verwendende reagenzien
DE69133552C5 (de) Nicht-A, nicht-B Hepatitis Virus Antigen, und diagnostische Verfahren.
DE770876T1 (de) Screening-Verfahren zur Ligand-Identifizierung von Zielproteinen
EP0774120B1 (de) Metallchelat-markierte peptide
Cover et al. Identification of proteins at the subunit interface of the Escherichia coli ribosome by cross-linking with dimethyl 3, 3'-dithiobis (propionimidate)
DE4430998A1 (de) Metallchelat-markierte Peptide
Burch et al. The relationships of cartilaginous fishes: an immunological study of serum transferrins of holocephalans and elasmobranchs
ATE225511T1 (de) Entstörung von diagnostischen verfahren durch peptide aus d-aminosäuren
Landis Promise and pitfalls in immunocytochemistry
Willard-Gallo et al. Leukocyte membrane proteins in chronic lymphocytic leukemia, as studied by two-dimensional gel electrophoresis.
EP0810230A3 (de) Anti-HIV-Antikörper als Kontrollproben
PT85960A (en) Process for the preparation of new polypeptides and their applications
DE69416453T2 (de) HCV-Peptide und deren Verwendung
DE68906096T2 (de) Synthetische antigene zur verwendung in der diagnose von malaria, induziert durch plasmodium vivax.
JPH08248034A (ja) タイプ特異的抗原を使用する血清学的タイプ分け方法
DE19540105C1 (de) Peptidzusammensetzungen zur Diagnose und zum Nachweis von Hepatitis C Virus (HCV)-Infektion
DE19549390C2 (de) Gespleißte Peptidzusammensetzungen zur Diagnose und zum Nachweis von Hepatitis C Virus (HCV)-Infektionen
KR930016541A (ko) 비-a, 비-b형 간염 바이러스의 중국인 분리물, 이를 함유하는 조성물 및 이를 이용하는 방법